pf-03882845
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00856258)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Mineralocorticoid receptorANTAGONIST
NR3C2 antagonist
Ph1 study terminated, development discontinued in 2012 (http://www.pfizer.com/sites/default/files/product-pipeline/pipeline_2012_1108.pdf)
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl- Mol. weight
- 419.91 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545175 ↗
- ChEMBLCHEMBL1215331 ↗
Also known as
- pf-03882845
- pf-03882845
- pf-03882845
- pf-03882845
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01488877 | Phase 1 | Jan 1, 2012 | Pfizer |
| NCT01445860 | Phase 1 | Aug 1, 2011 | Pfizer |
| NCT01314898 | Phase 1 | Mar 1, 2011 | Pfizer |
| NCT01366287 | Phase 1 | Jan 1, 2011 | Pfizer |
| NCT00971802 | Phase 1 | Sep 1, 2009 | Pfizer |
| NCT00856258 | Phase 1 | Mar 1, 2009 | Pfizer |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 1 | 2009 |
1 organizations
Page 1 / 1